Tag: size

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA), CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE IN THIS STOCK EXCHANGE RELEASE BELOW.
Series 1 tranche 1 offering of UAB „Atsinaujinančios energetikos investicijos“ notes under the EUR 25 million Bonds Programme is extended until 11-06-2026:
Closed – End Investment Company Intended for Informed Investors UAB “Atsinaujinančios energetikos investicijos” (hereinafter, the “Company”) is extending its public offering of series 1 tranche 1 EUR 2026/2027 Notes (ISIN LT000013780, hereinafter the “Notes”) until 11 June 2026, moving forward also the issue date of the Notes to 15 June 2026 and their maturity term to 15 July 2027. The Notes are being issued under the EUR 25 million Bond Programme. The base prospectus of the programme (hereinafter, the “Prospectus”) was approved by the Bank of Lithuania on 18 May 2026 and announced by the Company.
According to the final terms of the series 1 tranche 1, approved by the Company (hereinafter, the “Final Terms”, amended terms are attached, together with the Issue Specific Summary and translations thereof into Lithuanian, Latvian and Estonian), the Company is planning to issue up to EUR 5 million of nominal value Notes maturing on 15 July 2027 to investors in Lithuania, Latvia and Estonia.
Summary of the main issue terms:
Series 1 tranche 1 size: up to EUR 5,000,000
Denomination: EUR 1,000
Issue price of the Note: EUR 1,000
Interest rate: 9%
Subscription period: from 20 May 2026 to 11 June 2026 2:30 pm Vilnius time
Settlement and issue date: 15 June 2026
Maturity date: 15 July 2027
Investors wishing to submit a subscription order must contact their brokerage company. The investors, having provided their orders for participation in the offering, should not do anything additionally and their orders are valid, unless they would like to withdraw them, as indicated in the final terms.

MAIA’s novel telomere-targeting therapy being evaluated as a third-line treatment for advanced non-small cell lung cancer

New Location Marks 14th Store in Denver

Key Takeaways:

MINNEAPOLIS, June 03, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) (“Celcuity” or the “Company”), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications, today announced the pricing of its upsized underwritten public offering of $500,000,000 aggregate principal amount of its 0.250% convertible senior notes due 2032 (the “Convertible Notes”). The aggregate principal amount of the offering was increased from the previously announced offering size of $400,000,000.